Delivery Order SPE2DB20D3303-SPE2DB25FA2YH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $25,366.11 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Xifaxan is a non-systemic antibiotic used primarily in the treatment of traveler's...
- The Defense Logistics Agency awarded a delivery order valued at $6,348.06 to AmerisourceBergen Drug Corp for 60-tablet bottles of Xifaxan 550 mg on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Xifaxan is an antibiotic used to treat traveler's diarrhea and other gastrointestinal conditions, supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $9,260.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60-tablet units of Xifaxan 550 mg tablets, with an ultimate completion date of August 18, 2025. This non-set-aside delivery order was competitively awarded on August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Xifaxan is a non-absorbed antibiotic commonly used in military and federal healthcare settings for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $20,573.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is categorized as a child contract under AmerisourceBergen's broader federal contract portfolio. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,985.98 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units). This non-set-aside, competitively awarded contract utilizes firm fixed price terms with an ultimate completion date of August 18, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery from its Pennsylvania facility. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $71,126.78. The award was made on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside contract represents a competitive award to the pharmaceutical distributor, with performance to be fulfilled at the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Xifaxan 550 mg tablets in unit dose packaging (60 count) with a ceiling value of $1,625.31. This competitively awarded, firm fixed price delivery order is scheduled for completion by July 24, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) valued at $2,759.13. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents performance at the vendor's Conshohocken, Pennsylvania location. The award carries no set-aside designation, indicating it was competitively awarded through open competition. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $28,942.08. This firm fixed-price delivery order, which is expected to be completed by August 25, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains operations as a...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA2YHDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,434.78 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Xifaxan is a gastrointestinal antibiotic commonly used to treat traveler's diarrhea and hepatic encephalopathy, representing one of many pharmaceutical products that AmerisourceBergen supplies through federal contracts. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle serves as a comprehensive pharmaceutical supply mechanism for military and veteran healthcare systems worldwide, enabling the company to deliver a broad portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. AmerisourceBergen's continued award of competitively bid delivery orders under this IDC demonstrates the company's established capability as a critical pharmaceutical distributor supporting the Defense Health Agency and broader Department of Defense medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 8/22/25 |